{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:37:43Z","timestamp":1771591063988,"version":"3.50.1"},"reference-count":34,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100003227","name":"Osteogenesis Imperfecta Foundation and NIAMS","doi-asserted-by":"publisher","award":["P30AR072583"],"award-info":[{"award-number":["P30AR072583"]}],"id":[{"id":"10.13039\/100003227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Osteogenesis imperfecta (OI) is a genetic disorder characterized by increased bone fragility. Despite this, the use of antifracture drugs (AFD) among people with OI in the United States is not known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study examined the rates and types of AFD use in OI and whether use patterns varied with age, sex, and clinical severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cohort study using medical and prescription claims data from January 1, 2011, to December 31, 2022, in MarketScan and from January 1, 2006, to December 31, 2021, in a 5% Medicare sample. Durable medical equipment claims for long-term wheelchair were used to define severe OI. Each individual with OI was matched to 5 reference patients within the same database by year of birth, sex, race, index year, and baseline enrollment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 6494 people with OI and 32,470 individuals. The median [interquartile range] age was 21 years [8-43]. Adults comprised 55.8% of cohort; 57.6% were female. AFD use was 25.9% in the overall OI cohort and was higher in the severe OI group than in the milder group (38.3% vs 22.9%, respectively; standard mean difference 0.34). Use was highest in children, was much lower in young adults, and rose gradually with increasing age. Bisphosphonates were the most prescribed AFD across all age groups and OI severity levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that AFDs drugs are underutilized in the general US population of adults and children with OI. Our observed rates are lower than those reported in other studies, likely because our cohort reflects individuals in the general community rather than patients treated in specialized bone clinics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf514","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:01:37Z","timestamp":1757592097000},"page":"e778-e786","source":"Crossref","is-referenced-by-count":2,"title":["Rates and Pattern of Antifracture Drug Use in 6475 Adults and Children With Osteogenesis Imperfecta"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-0336","authenticated-orcid":false,"given":"Winnie","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University , Portland, OR 97239 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham , Birmingham, AL 35294 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanette","family":"Daigle","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science Technology Education and Research , Hoover, AL 35244 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglong","family":"Xie","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science Technology Education and Research , Hoover, AL 35244 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham , Birmingham, AL 35294 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-6439","authenticated-orcid":false,"given":"Lars","family":"Folkestad","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Bone and Minerals Unit, Odense University Hospital , 5000 Odense ,","place":["Denmark"]},{"name":"Department of Clinical Research, University of Southern Denmark , 5230 Odense ,","place":["Denmark"]},{"name":"KMEB, University of Southern Denmark , 5230 Odense ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Holladay","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham , Birmingham, AL 35294 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham , Birmingham, AL 35294 ,","place":["USA"]},{"name":"Foundation for Advancing Science Technology Education and Research , Hoover, AL 35244 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-7355","authenticated-orcid":false,"given":"Eric S","family":"Orwoll","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University , Portland, OR 97239 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"1","key":"2026021918531030300_dgaf514-B1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jbmr.2920","article-title":"Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study","volume":"32","author":"Folkestad","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026021918531030300_dgaf514-B2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"issue":"4","key":"2026021918531030300_dgaf514-B3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jbmr.2835","article-title":"Bone material properties in osteogenesis imperfecta","volume":"31","author":"Bishop","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026021918531030300_dgaf514-B4","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age*","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2026021918531030300_dgaf514-B5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"issue":"9902","key":"2026021918531030300_dgaf514-B6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"2026021918531030300_dgaf514-B7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","article-title":"Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy","volume":"18","author":"Rauch","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026021918531030300_dgaf514-B8","doi-asserted-by":"crossref","first-page":"e10118","DOI":"10.1002\/jbm4.10118","article-title":"A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis Imperfecta","volume":"3","author":"Bains","year":"2019","journal-title":"JBMR Plus"},{"issue":"3","key":"2026021918531030300_dgaf514-B9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2106\/JBJS.L.01596","article-title":"Behavior of scoliosis during growth in children with osteogenesis imperfecta","volume":"96","author":"Anissipour","year":"2014","journal-title":"J Bone Joint Surg Am"},{"issue":"10","key":"2026021918531030300_dgaf514-B10","first-page":"Cd005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2026021918531030300_dgaf514-B11","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/jbmr.2895","article-title":"Mortality and causes of death in patients with osteogenesis Imperfecta: a register-based nationwide cohort study","volume":"31","author":"Folkestad","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026021918531030300_dgaf514-B12","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1111\/dom.15914","article-title":"Prevalence of complications and co-morbidities in males and females with obesity: real-world insights from claims data analysis","volume":"26","author":"Bae","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2026021918531030300_dgaf514-B13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1089\/thy.2023.0651","article-title":"Does the adoption of molecular testing cause decreased thyroidectomy rates in a national cohort? A quasiexperimental study of high- versus low-adoption states","volume":"34","author":"Huang","year":"2024","journal-title":"Thyroid"},{"key":"2026021918531030300_dgaf514-B14","doi-asserted-by":"crossref","unstructured":"Liu W, Shanette Daigle JZ, Xie F, et al \u00a0Data from: rates and pattern of anti-fracture drug use in 6475 adults and children with osteogenesis imperfecta. Zenodo. doi:10.5281\/zenodo.16767993. Deposited 7 August 2025.","DOI":"10.1210\/clinem\/dgaf514"},{"issue":"5","key":"2026021918531030300_dgaf514-B15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/01241398-200409000-00011","article-title":"The functional mobility scale (FMS)","volume":"24","author":"Graham","year":"2004","journal-title":"J Pediatr Orthop"},{"issue":"10","key":"2026021918531030300_dgaf514-B16","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/s41436-019-0491-4","article-title":"Mobility in osteogenesis imperfecta: a multicenter north American study","volume":"21","author":"Kruger","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"2026021918531030300_dgaf514-B17","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"2026021918531030300_dgaf514-B18","doi-asserted-by":"crossref","first-page":"e10782","DOI":"10.1002\/jbm4.10782","article-title":"The natural history of symptomatic fractures in children and adolescents with osteogenesis Imperfecta type 1: a cohort study from western Australia","volume":"7","author":"Joshi","year":"2023","journal-title":"JBMR Plus"},{"issue":"1","key":"2026021918531030300_dgaf514-B19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","article-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study","volume":"27","author":"Otaify","year":"2016","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026021918531030300_dgaf514-B20","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"3","key":"2026021918531030300_dgaf514-B21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apa.14154","article-title":"Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings","volume":"107","author":"Li","year":"2018","journal-title":"Acta Paediatr"},{"issue":"1","key":"2026021918531030300_dgaf514-B22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13023-019-1197-z","article-title":"Individualized treatment with denosumab in children with osteogenesis imperfecta\u2014follow up of a trial cohort","volume":"14","author":"Hoyer-Kuhn","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2026021918531030300_dgaf514-B23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis Imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026021918531030300_dgaf514-B24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00223-024-01274-5","article-title":"Analyses of osteogenesis imperfecta in South Korea using the nationwide health insurance service claim data: a propensity score-matched study","volume":"115","author":"Park","year":"2024","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2026021918531030300_dgaf514-B25","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1210\/clinem\/dgad035","article-title":"Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta","volume":"108","author":"Liu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026021918531030300_dgaf514-B26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"issue":"2","key":"2026021918531030300_dgaf514-B27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","article-title":"Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta","volume":"87","author":"Shapiro","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2026021918531030300_dgaf514-B28","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00198-024-07051-2","article-title":"Demographics and medical burden of osteogenesis imperfecta: a nationwide database analysis","volume":"35","author":"Shih","year":"2024","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026021918531030300_dgaf514-B29","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1007\/s00198-016-3653-0","article-title":"Skeletal phenotypes in adult patients with osteogenesis imperfecta\u2014correlations with COL1A1\/COL1A2 genotype and collagen structure","volume":"27","author":"Hald","year":"2016","journal-title":"Osteoporos Int"},{"issue":"1-2","key":"2026021918531030300_dgaf514-B30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","article-title":"Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta","volume":"6","author":"Wekre","year":"2011","journal-title":"Arch Osteoporos"},{"key":"2026021918531030300_dgaf514-B31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bonr.2018.04.009","article-title":"Adults with osteogenesis imperfecta: clinical characteristics of 151 patients with a focus on bisphosphonate use and bone density measurements","volume":"8","author":"Scheres","year":"2018","journal-title":"Bone Rep"},{"issue":"3","key":"2026021918531030300_dgaf514-B32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11926-011-0168-8","article-title":"Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies","volume":"13","author":"Zhang","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"13","key":"2026021918531030300_dgaf514-B33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2012.404","article-title":"Finding pure and simple truths with administrative data","volume":"307","author":"Sarrazin","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"2026021918531030300_dgaf514-B34","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s12325-016-0360-3","article-title":"Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates","volume":"33","author":"Goldshtein","year":"2016","journal-title":"Adv Ther"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf514\/64247645\/dgaf514.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/3\/e778\/64247645\/dgaf514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/3\/e778\/64247645\/dgaf514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:53:20Z","timestamp":1771545200000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/3\/e778\/8251769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,11]]},"published-print":{"date-parts":[[2026,2,20]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf514","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,11]]}}}